[1]中华人民共和国卫生部. 全国结核病耐药性基线调查报告(2007—2008年). 北京:人民卫生出版社,2010.[2]Williams DL, Waguespack C, Eisenach K, et al. Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother, 1994, 38(10): 2380-2386.[3]Chaves F, Alonso-Sanz M, Rebollo MJ, et al. rpoB mutations as an epidemiologic marker in rifampin-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis, 2000, 4(8): 765-770.[4]黄海荣,金奇,马玙,等. 中国耐利福平结核分枝杆菌rpoB基因突变特点. 中华结核和呼吸杂志,2001,24(4):231-235.[5]Williams DL, Spring L, Collins L, et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 1998, 42(7):1853-1857.[6]Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet, 2001, 40(5):327-341.[7]赵雁林.结核病实验室诊断技术培训教程.北京:人民卫生出版社,2014.[8]Leonard B, Coronel J, Siedner M, et al. Inter- and intra-assay reproducibility of microplate Alamar blue assay results for isoniazid, rifampicin, ethambutol, streptomycin, ciprofloxacin, and capreomycin drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol, 2008, 46(10): 3526-3529.[9]韩喜琴,黄海荣,李艳静,等. 利福平和利福布丁对结核分枝杆菌交叉耐药率的初步探讨. 中国防痨杂志,2010,32(11):740-743.[10]高丽,肖和平,胡忠义,等. 耐多药结核分枝杆菌对利福布丁和利福平的交叉耐药性分析. 中华结核和呼吸杂志,2012,35(5):333-335.[11]梁庆福,陈求扬,林淑芳,等.福建省耐多药结核分枝杆菌利福平耐药rpoB基因突变特征.中国卫生检疫杂志,23(7):1649-1651.[12]苏雯婕,苏政军,孟繁荣,等.95例耐多药结核菌株rpoB基因突变的分子特征.实用医学杂志,2012,28(14):2333-2335.[13]Schon T, Juréen P, Chryssanthou E, et al. Rifampicin-resis-tant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact? J Antimicrob Chemother, 2013, 68(9):2074-2077.[14]Chikamtsu K, Mizuno K, Yamada H, et al. Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains. Kekkaku, 2009, 84(9):631-633.[15]Pang Y, Lu J, Wang Y, et al. Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2013, 57(2): 893-900.[16]胡族琼,谭耀驹,罗春明,等. 广东地区结核分枝杆菌利福布丁耐药株rpoB全基因序列突变特征. 中国人兽共患病学报,2011,27(11):980-982.[17]Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J, 2005, 25(3):564-569. |